Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
6(60%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_1
4
40%
Ph phase_3
2
20%
Ph phase_2
4
40%

Phase Distribution

4

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
4(40.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

10

all time

Status Distribution
Active(7)
Completed(1)
Other(2)

Detailed Status

Recruiting5
Active, not recruiting1
Not yet recruiting1
Completed1
Suspended1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
6
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (40.0%)
Phase 24 (40.0%)
Phase 32 (20.0%)

Trials by Status

active_not_recruiting110%
not_yet_recruiting110%
completed110%
suspended110%
recruiting550%
unknown110%

Recent Activity

6 active trials
Showing 5 of 10
recruitingphase_1

A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

NCT07334301
recruitingphase_2

Quadruple Immunotherapy for Neuroblastoma

NCT05754684
recruitingphase_1

Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma

NCT06485947
recruitingphase_3

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

NCT04221035
not_yet_recruitingphase_1

International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma

NCT06839703
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07334301Phase 1

A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

Recruiting
NCT05754684Phase 2

Quadruple Immunotherapy for Neuroblastoma

Recruiting
NCT06485947Phase 1

Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma

Recruiting
NCT04221035Phase 3

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting
NCT06839703Phase 1

International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma

Not Yet Recruiting
NCT06669013Phase 3

Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas

Recruiting
NCT05373901Phase 1

Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma

Completed
NCT02308527Phase 2

Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children

Active Not Recruiting
NCT05558280Phase 2

Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma

Suspended
NCT02743429Phase 2

Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10